Pathstone Holdings
MDGL icon

Pathstone Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

Pathstone Holdings’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.86M Buy
5,457
+724
+15% +$346K 0.01% 843
2025
Q4 		$2.76M Buy
4,733
+2,297
+94% +$1.17M 0.01% 861
2025
Q3 		$1.12M Buy
+2,436
New +$909K ﹤0.01% 1352

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Holdings's MDGL Position: Q1 2026 in Review

Pathstone Holdings increased its Madrigal Pharmaceuticals (MDGL) stake by 15% in Q1 2026, buying an estimated $346K and bringing the position to 5,457 shares worth $2.86M. The position accounts for 0.01% of the portfolio, ranked #843.

Pathstone Holdings first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Pathstone Holdings held 5,457 shares of Madrigal Pharmaceuticals worth $2.86M as of Q1 2026.
  • Pathstone Holdings bought 724 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $346K.
  • Madrigal Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q1 2026, its #843 holding.
  • Pathstone Holdings first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.